Table of Contents (PDF)

Home , Olaratumab, Trastuzumab deruxtecan

July 15, 2021 | Volume 27 | Number 14

CLINICAL CANCER RESEARCH TABLE OF CONTENTS

HIGHLIGHTS CLINICAL TRIALS: TARGETED THERAPY

3805 Selected Articles from This Issue 3834 Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced SPECIAL FEATURES Solid Tumors A C Naoko Takebe, Abdul Rafeh Naqash, CCR Translations Geraldine O’Sullivan Coyne, Shivaani Kummar, Khanh Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, 3807 Did Everolimus Break the Rules? Larry Rubinstein, Richard Piekarz, Elad Sharon, Shumei Kato and Ezra E.W. Cohen Howard Streicher, Arjun Mittra, Sarah B. Miller, Jiuping Ji, Deborah Wilsker, Robert J. Kinders, See related article, p. 3845 Ralph E. Parchment, Li Chen, Ting-Chia Chang, Biswajit Das, Ganesh Mugundu, James H. Doroshow, 3809 Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue and Alice P. Chen Sarcomas: The Road to Cardioprotection Robert S. Benjamin and Giorgio Minotti 3845 Phase II Clinical Trial of Everolimus in a Pan-Cancer See related articles, p. 3854 and p. 3861 Cohort of Patients with mTOR Pathway Alterations Elio Adib, Katarzyna Klonowska, Krinio Giannikou, 3812 Putting the Microenvironment into the Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Immunotherapy Companion Diagnostic Matthew I. Milstein, Jennifer Hedglin, Myrto Moutafi and David L. Rimm Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, See related article, p. 3926 David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, 3815 (Chemo)Radiotherapy–Immunotherapy Gopa Iyer, and David J. Kwiatkowski Combinations: Time to Get Tailored? See related commentary, p. 3807 Michele Mondini and Eric Deutsch See related article, p. 3990 3854 Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Reviews Sarcoma A C Brian A. Van Tine, Angela C. Hirbe, Peter Oppelt, 3818 Type I IFN Activating Type I Dendritic Cells for Ashley E. Frith, Richa Rathore, Joshua D. Mitchell, Antitumor Immunity Fei Wan, Shellie Berry, Michele Landeau, Yong Liang, Raquibul Hannan, and Yang-Xin Fu George A. Heberton, John Gorcsan III, Peter R. Huntjens, Yoku Soyama, Justin M. Vader, 3825 Refining the Molecular Framework for Pancreatic Jose A. Alvarez-Cardona, Kathleen W. Zhang, Cancer with Single-cell and Spatial Technologies Daniel J. Lenihan, and Ronald J. Krone Jimmy A. Guo, Hannah I. Hoffman, Colin D. Weekes, See related commentary, p. 3809 Lei Zheng, David T. Ting, and William L. Hwang

3861 Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial A C Robin L. Jones, Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine, Javier Martín-Broto, Patrick M. Peterson, Jennifer Wright, and William D. Tap See related commentary, p. 3809

3867 A Phase I Study of Alpelisib in Combination with CLINICAL TRIALS: IMMUNOTHERAPY Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic 3916 Modified RANO, Immunotherapy RANO, and Breast Cancer Standard RANO Response to Convection-Enhanced KomalJhaveri,JoshuaZ.Drago,PayalDeepakShah, Delivery of IL4R-Targeted Immunotoxin MDNA55 in Rui Wang, Fresia Pareja, Fanni Ratzon, Recurrent Glioblastoma Alexia Iasonos, Sujata Patil, Neal Rosen, Benjamin M. Ellingson, John Sampson, Monica N. Fornier, Nancy T. Sklarin, Achal Singh Achrol, Manish K. Aghi, Sarat Chandarlapaty, and Shanu Modi Krystof Bankiewicz, Chencai Wang, Martin Bexon, Steven Brem, Andrew Brenner, Sajeel Chowdhary, 3876 Phase I–II Open-Label Multicenter Study of John R. Floyd, Seunggu Han, Santosh Kesari, þ BRAFV600MUT Palbociclib Vemurafenib in Dina Randazzo, Michael A. Vogelbaum, Metastatic Melanoma Patients: Uncovering CHEK2 Frank Vrionis, Miroslaw Zabek, Nicholas Butowski, as a Major Response Mechanism Melissa Coello, Nina Merchant, and Fahar Merchant Baptiste Louveau, Matthieu Resche-Rigon, Thierry Lesimple, Laetitia Da Meda, Marc Pracht, 3926 Analyses of PD-L1 and Inflammatory Gene Barouyr Baroudjian, Julie Delyon, Mona Amini-Adle, Expression Association with Efficacy of Nivolumab Caroline Dutriaux, Coralie Reger de Moura, Ipilimumab in Gastric Cancer/Gastroesophageal Aurelie Sadoux, Fanelie Jouenne, Zineb Ghrieb, Junction Cancer Paul Vilquin, Didier Bouton, Annick Tibi, A C Ming Lei, Nathan O. Siemers, Dimple Pandya, Samuel Huguet, Keyvan Rezai, Maxime Battistella, Han Chang, Teresa Sanchez, Christopher Harbison, Samia Mourah, and Celeste Lebbe Peter M. Szabo, Yelena Janjigian, Patrick A. Ott, Padmanee Sharma, Johanna Bendell, 3884 Veliparib in Combination with Carboplatin and Thomas R. Jeffry Evans, Filippo de Braud, Ian Chau, Etoposide in Patients with Treatment-Naïve and Zachary Boyd Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study See related commentary, p. 3812 Lauren Averett Byers, Dmitry Bentsion, Steven Gans, Konstantin Penkov, ChoonHee Son, Anne Sibille, PRECISION MEDICINE AND IMAGING Taofeek K. Owonikoko, Harry J.M. Groen, Carl M. Gay, Junya Fujimoto, Patricia de Groot, Martin Dunbar, 3936 A Novel Topical Fluorescent Probe for Detection of Kingston Kang, Lei He, Vasudha Sehgal, Glioblastoma Jaimee Glasgow, Bruce Allen Bach, and Peter M. Ellis Yosuke Kitagawa, Shota Tanaka, Mako Kamiya, Yugo Kuriki, Kyoko Yamamoto, Takenori Shimizu, 3896 Clinical and Biomarker Results from Phase I/II Study of Takahide Nejo, Taijun Hana, Reiko Matsuura, PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2- Tsukasa Koike, Erika Yamazawa, Yoshihiro Kushihara, Negative Metastatic Breast Cancer Satoshi Takahashi, Masashi Nomura, Hirokazu Takami, Priyanka Sharma, Vandana G. Abramson, Anne O’Dea, Shunsaku Takayanagi, Akitake Mukasa, Lauren Nye, Ingrid Mayer, Harsh B. Pathak, Yasuteru Urano, and Nobuhito Saito Marc Hoffmann, Shane R. Stecklein, Manana Elia, Sharon Lewis, Jecinta Scott, Jilliann A. De Jong, 3948 Deep Learning for Fully Automated Prediction of Yen Y. Wang, Rachel Yoder, Kelsey Schwensen, Overall Survival in Patients with Oropharyngeal Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Cancer Using FDG-PET Imaging Stephen K. Williamson, Milind A. Phadnis, Nai-Ming Cheng, Jiawen Yao, Jinzheng Cai, Gregory A. Reed, Bruce F. Kimler, Qamar J. Khan, and Xianghua Ye, Shilin Zhao, Kui Zhao, Wenlan Zhou, Andrew K. Godwin Isabella Nogues, Yuankai Huo, Chun-Ta Liao, Hung-Ming Wang, Chien-Yu Lin, Li-Yu Lee, Jing Xiao, 3905 First-in-Human Phase 1 Study of MORAb-202, an Le Lu, Ling Zhang, and Tzu-Chen Yen Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate 3960 Whole-Genome Sequencing of Common Salivary Receptor-a–Positive Advanced Solid Tumors Gland Carcinomas: Subtype-Restricted and Shared Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Genetic Alterations Takafumi Koyama, Jun Sato, Kenji Tamura, Tatiana V. Karpinets, Yoshitsugu Mitani, Bin Liu, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Jianhua Zhang, Kristen B. Pytynia, Linton D. Sellen, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, and Danice T. Karagiannis, Renata Ferrarotto, Noboru Yamamoto Andrew P. Futreal, and Adel K. El-Naggar

3970 Visualization of Intratumor Pharmacokinetics of 4036 Fibroblast Activation Protein a-Targeted CD40 [fam-] Trastuzumab Deruxtecan (DS-8201a) Agonism Abrogates Systemic Toxicity and Enables in HER2 Heterogeneous Model Using Administration of High Doses to Induce Effective Phosphor-integrated Dots Imaging Analysis Antitumor Immunity Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Eva Sum, Moritz Rapp, Philipp Frobel,€ Marine Le Clech, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Harald Durr,€ Anna Maria Giusti, Mario Perro, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Dario Speziale, Leo Kunz, Elena Menietti, Kan Yonemori, Kenji Tamura, Kosei Hasegawa, and Peter Brunker,€ Ulrike Hopfer, Martin Lechmann, Akinobu Hamada Andrzej Sobieniecki, Birte Appelt, Roberto Adelfio, Valeria Nicolini, Anne Freimoser-Grundschober, 3980 Steroid Ligands, the Forgotten Triggers of Nuclear Whitney Jordaan, Sara Labiano, Felix Weber, Receptor Action; Implications for Acquired Resistance Thomas Emrich, Francois¸ Christen, Birgit Essig, to Endocrine Therapy Pedro Romero, Christine Trumpfheller, and Rachel Bleach, Stephen F. Madden, James Hawley, Pablo Umaña Sara Charmsaz, Cigdem Selli, Katherine M. Sheehan, Leonie S. Young, Andrew H. Sims, Pavel Soucek, 4054 CD40 Agonist Targeted to Fibroblast Activation Arnold D. Hill, and Marie McIlroy Protein a Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors TRANSLATIONAL CANCER MECHANISMS AND Sara Labiano, Vincent Roh, Celine Godfroid, Agnes Hiou-Feige, Jackeline Romero, Eva Sum, THERAPY Moritz Rapp, Gael Boivin, Tania Wyss, Christian Simon, Jean Bourhis, Pablo Umaña, 3990 Heterogeneity of IFN-Mediated Responses and Tumor Christine Trumpfheller, Genrich V. Tolstonog, Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy Marie-Catherine Vozenin, and Pedro Romero Jianzhou Chen, Chuangzhen Chen, Yizhou Zhan, 4066 Comprehensive Molecular and Clinicopathologic Li Zhou, Jie Chen, Qingxin Cai, Yanxuan Wu, Analysis of 200 Pulmonary Invasive Mucinous Zhihan Sui, Chengbing Zeng, Xiaolong Wei, and Adenocarcinomas Identifies Distinct Characteristics Ruth Muschel of Molecular Subtypes See related commentary, p. 3815 Jason C. Chang, Michael Offin, Christina Falcon, David Brown, Brian R. Houck-Loomis, Fanli Meng, 4003 Recurrent Mutations in Cyclin D3 Confer Clinical Vasilisa A. Rudneva, Helen H. Won, Sharon Amir, Resistance to FLT3 Inhibitors in Acute Myeloid Joseph Montecalvo, Patrice Desmeules, Kyuichi Kadota, Leukemia Prasad S. Adusumilli, Valerie W. Rusch, Sarah Teed, Catherine C. Smith, Aaron D. Viny, Evan Massi, Joshua K. Sabari, Ryma Benayed, Khedoudja Nafa, Cyriac Kandoth, Nicholas D. Socci, Franck Rapaport, Laetitia Borsu, Bob T. Li, Alison M. Schram, Matthieu Najm, Juan S. Medina-Martinez, Maria E. Arcila, William D. Travis, Marc Ladanyi, Elli Papaemmanuil, Theodore C. Tarver, Henry H. Hsu, Alexander Drilon, and Natasha Rekhtman Mai H. Le, Brian West, Gideon Bollag, Barry S. Taylor, Ross L. Levine, and Neil P. Shah 4077 Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology 4012 Global Phosphoproteomics Reveal CDK Suppression and Poor Outcomes in Men with mCRPC Treated with as a Vulnerability to KRas Addiction in Pancreatic Abiraterone or Enzalutamide Cancer Landon C. Brown, Susan Halabi, Joseph D. Schonhoft, Aslamuzzaman Kazi, Liwei Chen, Shengyan Xiang, Qian Yang, Jun Luo, David M. Nanus, Rajanikanth Vangipurapu, Hua Yang, Francisca Beato, Paraskevi Giannakakou, Russell Z. Szmulewitz, Bin Fang, Terence M. Williams, Kazim Husain, Daniel C. Danila, Ethan S. Barnett, Emily A. Carbone, Patrick Underwood, Jason B. Fleming, Mokenge Malafa, Jimmy L. Zhao, Patrick Healy, Monika Anand, Eric A. Welsh, John Koomen, Jose Trevino, and Audrey Gill, Adam Jendrisak, William R. Berry, Saïd M. Sebti Santosh Gupta, Simon G. Gregory, Richard Wenstrup, Emmanuel S. Antonarakis, Daniel J. George, 4025 CDKN2A Alterations and Response to Immunotherapy Howard I. Scher, and Andrew J. Armstrong in Solid Tumors Elio Adib, Amin H. Nassar, Elie W. Akl, 4089 Single-cell Profiles and Prognostic Impact of Sarah Abou Alaiwi, Pier Vitale Nuzzo, Tumor-Infiltrating Lymphocytes Coexpressing Tarek H. Mouhieddine, Guru Sonpavde, CD39, CD103, and PD-1 in Ovarian Cancer Robert I. Haddad, Kent W. Mouw, Marios Giannakis, Celine M. Laumont, Maartje C.A. Wouters, F. Stephen Hodi, Sachet A. Shukla, Alexander Gusev, Julian Smazynski, Nicole S. Gierc, Elizabeth A. Chavez, David A. Braun, Toni K. Choueiri, and Lauren C. Chong, Shelby Thornton, Katy Milne, David J. Kwiatkowski John R. Webb, Christian Steidl, and Brad H. Nelson

vii

4101 Intrahepatic Cholangiocarcinoma with Lymph Node 4127 The Proteomic Landscape of Pancreatic Ductal Metastasis: Treatment-Related Outcomes and the Adenocarcinoma Liver Metastases Identifies Role of Tumor Genomics in Patient Selection Molecular Subtypes and Associations with Clinical Joshua S. Jolissaint, Kevin C. Soares, Kenneth P. Seier, Response—Response Ritika Kundra, Mithat Gonen,€ Paul J. Shin, Henry C.-H. Law, Emalie J. Clement, Thomas Boerner, Carlie Sigel, Ramyasree Madupuri, Paul M. Grandgenett, Michael A. Hollingsworth, and Efsevia Vakiani, Andrea Cercek, James J. Harding, Nicholas T. Woods Nancy E. Kemeny, Louise C. Connell, ’ Vinod P. Balachandran, Michael I. D Angelica, CORRECTIONS Jeffrey A. Drebin, T. Peter Kingham, Alice C. Wei, and William R. Jarnagin 4128 Correction: Glycogen Synthase Kinase-3 Inhibition 4109 Single-Cell Characterization of the Immune Sensitizes Pancreatic Cancer Cells to Chemotherapy – Microenvironment of Melanoma Brain and by Abrogating the TopBP1/ATR mediated DNA Leptomeningeal Metastases Damage Response Inna Smalley, Zhihua Chen, Manali Phadke, Li Ding, Vijay S. Madamsetty, Spencer Kiers, Jiannong Li, Xiaoqing Yu, Clayton Wyatt, Olga Alekhina, Andrey Ugolkov, John Dube, Yu Zhang, Brittany Evernden, Jane L. Messina, Amod Sarnaik, Jin-San Zhang, Enfeng Wang, Shamit K. Dutta, Vernon K. Sondak, Chaomei Zhang, Vincent Law, Daniel M. Schmitt, Francis J. Giles, Alan P. Kozikowski, Nam Tran, Arnold Etame, Robert J.B. Macaulay, Andrew P. Mazar, Debabrata Mukhopadhyay, and Zeynep Eroglu, Peter A. Forsyth, Paulo C. Rodriguez, Daniel D. Billadeau Y. Ann Chen, and Keiran S.M. Smalley 4129 Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for LETTERS TO THE EDITOR Targeted HER3 Therapy in HPVþ Patients 4126 The Proteomic Landscape of Pancreatic Ductal Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Adenocarcinoma Liver Metastases Identifies Noah D. Peyser, Hua Li, Yan Zeng, Molecular Subtypes and Associations with Clinical Erin Isaacson Wechsler, Max V. Ranall, Response—Letter Sourav Bandyopadhyay, Umamaheswar Duvvuri, Tessa Y.S. Le Large, Lenka N.C. Boyd, Geert Kazemier, Theresa M. LaVallee, Richard C.K. Jordan, and Elisa Giovannetti Daniel E. Johnson, and Jennifer R. Grandis

A C AC icon indicates AuthorChoice For more information please visit www.aacrjournals.org

ABOUT THE COVER

The image shows a pulmonary invasive mucinous adenocarcinoma (IMA)—a clinicopathologi- cally and molecularly highly distinct subtype of lung adenocarcinoma. The tumor in the image harbors an NRG1 fusion; this type of IMA was found to exhibit more aggressive histologic and clinical features compared with IMA with KRAS mutations. Among KRAS wild-type IMA, NRG1 and other fusions were identified in over half of the cases, leading to durable responses to targeted therapies in some patients, which highlights the importance of fusion testing in this tumor type. For details, see the article by Chang and colleagues on page 4066 of this issue.

viii

Clin Cancer Res 2021;27:3805-4129.

Updated version Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/27/14

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at Subscriptions [email protected].

Permissions To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/27/14. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.